InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+10.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by HENNEY CHRISTOPHER S, Director. Insider active across 2 companies, notably Cyclacel Pharmaceuticals, Inc.. In total, 12 disclosures have been published. Activity tracked since 15 June 2021. The latest transaction was disclosed on 30 June 2023 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
21,219 shares0Common StockSEC:0001104659-23-077651:0
15,822 shares0Common StockSEC:0001104659-22-071893:0
11,108 shares@ US$11.339.8% of flowOrdinary Shares, par value $0.01 per shareSEC:0001567619-21-013567
11,108 shares@ US$11.330.021% mcap9.8% of flowOrdinary Shares, par value $0.01 per shareSEC:0001567619-21-013567:0
17,500 shares@ US$9.2312.5% of flowOrdinary Shares, par value $0.01 per shareSEC:0001140361-21-024235
17,500 shares@ US$9.230.026% mcap12.5% of flowOrdinary Shares, par value $0.01 per shareSEC:0001140361-21-024235:0
17,500 shares@ US$9.2312.5% of flowOrdinary Shares, par value $0.01 per shareSEC:0001140361-21-024156
17,500 shares@ US$9.230.026% mcap12.5% of flowOrdinary Shares, par value $0.01 per shareSEC:0001140361-21-024156:0
12,000 shares@ US$16.4315.2% of flowOrdinary Shares, par value $0.01 per shareSEC:0001567619-21-012739
12,000 shares@ US$16.430.032% mcap15.2% of flowOrdinary Shares, par value $0.01 per shareSEC:0001567619-21-012739:0
2,374 shares0Common StockSEC:0001104659-21-082599:0
2,374 shares0Common StockSEC:0001104659-21-082599
12 of 12 declarations
About HENNEY CHRISTOPHER S
Christopher S. Henney is a Board Member at Cyclacel Pharmaceuticals, Inc. and PROTHENA CORP PUBLIC LTD CO. In these roles, he contributes to the governance of the companies and strategic decision-making. His experience in the pharmaceutical sector allows him to bring valuable insights to help guide development and innovation strategies.
